2ND AND 3RD LINE TREATMENT FOR HER2-POSITIVE METASTATIC BREAST CANCER¹
`TOTAL PROMOTIONAL EXPENDITURES
`U.S. DOLLARS BY PRODUCT, INCLUDING GENERICS
`Q4 2012 – Q3 2014
`
`2012
`
`Q4
`
`Q1
`
`Q2
`
`Q3
`
`Q4
`
`Q1
`
`2013
`
`2014
`
`Q2
`
`Q3
`
`Total
`
`Ixempra®
`Kadcyla®
`Perjeta®
`Tykerb®
`Xeloda®
`
`
`
`Total
`
`$225,484
`
`$847,418
`$399,444
`$135,723
`
`
`
`$129,141
`$736,683
`$468,237
`$85,555
`$6,140,868
`
`
`
`$280,673
`$803,638
`$430,085
`$61,090
`$181,542
`
`
`
`$94,955
`$513,205
`$549,066
`$18,900
`$665,104
`
`
`
`$32,188
`$647,224
`$750,148
`$1,367,854
`$1,280,831
`
`
`
`$432,766
`$514,562
`$378,274
`
`$64,068
`$402,839
`$970,978
`
`$32,564
`$400,703
`$624,435
`
`
`
`$30,525
`
`
`
`$376,989
`
`
`
`
`
`$1,291,839
`$4,018,854
`$5,018,641
`$1,932,843
`$8,811,582
`
`$1,608,069
`
`$7,560,484
`
`$1,757,028
`
`$1,841,230
`
`$4,078,245
`
`$1,356,127
`
`$1,814,874
`
`$1,057,702
`
`$21,073,759
`
`Notes & Sources:
`¹ Excludes Herceptin®.
`Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® and a taxane
`chemotherapy. See, e.g., Exhibit 2317. In contrast:
`Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.
`Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.
`Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2342.
`(These assertions and sources can be found in the report.)
`Includes brand and generic values.
`Ixempra® includes brand IXEMPRA 10/2007 BM0, identified in field 'Product.'
`Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'
`Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'
`Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'
`Xeloda® includes brand XELODA 05/1998 GTC, identified in field 'Product,' and generic capecitabine, identified in field 'Combined Molecule.'
`Includes Xeloda® (capecitabine), which is indicated for use with Tykerb® (lapatinib) in second-line therapy. Excludes other chemotherapeutic agents that may be used to treat breast
`cancer (e.g., vinorelbine), which are indicated for the use of other cancers. See Exhibit 2218 and Exhibit 2343.
`Values reflect field 'Total Promo $'.
`Products identified from Exhibit 2103 and Exhibit 2224.
`Data from IMS Health.
`
`IMMUNOGEN 2319, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676